GLP-1 Therapies and Hair Loss: A Systematic Review of Current Evidence and Implications for Counseling

    April 2026 in “ Science Progress ”
    Aditya K. Gupta, Elizabeth M. Teasell, Vasiliki Economopoulos, Paradi Mirmirani
    Studysummary This study found that among users of glucagon-like peptide-1 receptor agonists, semaglutide and tirzepatide were associated with higher incidences of hair loss, particularly androgenetic alopecia and telogen effluvium, with rapid weight loss identified as a potential contributor to telogen effluvium.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on doi.org →
    Discuss this study in the Community →

    Research cited in this study 17

    1. Increased Risk of Telogen Effluvium with Tirzepatide Compared to Other Weight-Loss Medications: A Retrospective Cohort TriNetX Database Study Journal of the American Academy of Dermatology · 2025
    2. Association Between Androgenetic Alopecia and Glucagon-Like Peptide-1 Receptor Treatment in Type 2 Diabetes Mellitus Patients: A Retrospective Cohort Study International Journal of Dermatology · 2025
    3. Menopause and Hair Loss in Women: Exploring the Hormonal Transition Maturitas · 2025
    4. Dermatologic Implications of GLP-1 Receptor Agonist Medications: A Comprehensive Review Skin Appendage Disorders · 2025
    5. Exploring the Hair Loss Risk in Glucagon-Like Peptide-1 Agonists: Emerging Concerns and Clinical Implications Journal of the European Academy of Dermatology and Venereology · 2025
    6. Glucagon-Like Peptide-1 Receptor Agonist Medications and Hair Loss: A Retrospective Cohort Study Journal of the American Academy of Dermatology · 2025
    7. Frequency of Types of Alopecia in a Single-Center Hair Referral Clinic Over a Ten-Year Period International Journal of Trichology · 2025
    8. Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study Cardiovascular Drugs and Therapy · 2024
    9. Semaglutide and Hair Loss: A Real-World Analysis Journal of the American Academy of Dermatology · 2024
    10. Treatment of Insulin Resistance With Tirzepatide Leading to Improvement of Hair Loss JAAD Case Reports · 2024
    11. Telogen Effluvium Associated with Weight Loss: A Single Center Retrospective Study Annals of dermatology/Annals of Dermatology · 2024
    12. Overview of the Circadian Clock in the Hair Follicle Cycle Biomolecules · 2023
    13. Hair Loss in Patients With Gastroparesis: A Sign of Nutritional Deficiency? Digestive Diseases and Sciences · 2023
    14. Comparative Evaluation Between Two Nutritional Supplements in the Improvement of Telogen Effluvium Clinical, Cosmetic and Investigational Dermatology · 2018
    15. Hormones and Clocks: Do They Disrupt the Locks? Fluctuating Estrogen Levels During Menopausal Transition May Influence Clock Genes and Trigger Chronic Telogen Effluvium Dermatology Online Journal · 2016
    16. The Hair Follicle as an Estrogen Target and Source Endocrine Reviews · 2006
    17. Glucagon-Like Peptide-1 Receptor and Proglucagon Expression in Mouse Skin Regulatory Peptides · 2006